Following a highly successful career as an executive in the pharmaceutical industry, Ajay K. Ohri added to his responsibilities to pursue nonprofit management. Desiring to leave a legacy in his late wife’s name, he established The Alka Ohri Foundation, a 501(c)3 nonprofit organization, in 2023 after his wife passed away from metastatic breast cancer. To this end, Mr. Ohri aims to help others battling cancer and support cancer research initiatives through The Alka Ohri Foundation, particularly within the realm of holistic cancer treatment. Noting that many forms of holistic treatment are not encouraged due to a lack of resources or an unwillingness of insurance companies to reimburse costs, Mr. Ohri has endeavored to make a difference in the field. In addition, though some cancer patient advocacy groups and educational systems seek to improve the wellness of cancer patients undergoing treatment, many cancer foundations place little emphasis on improving their quality of life, which has inspired Mr. Ohri to develop solutions and improve the patient experience.
Notably, The Alka Ohri Foundation has made significant progress toward its goals despite being in its infancy, serving as a testament to Mr. Ohri’s profound leadership. Attributing much of his success to his optimistic attitude, responsiveness to the needs of those around him, and transparency in his interactions with others, Mr. Ohri has exemplified fortitude, evident in the organization’s continued success in its first several months of existence. Looking toward the future of The Alka Ohri Foundation, Mr. Ohri aims to help more women overcome breast cancer and improve their overall quality of life. Furthermore, he wishes to empower women by educating them on holistic treatment methodologies, allowing them to lead a healthy and active life during their battle with cancer. Impressively, Mr. Ohri intends to share his organization and message across the world so patients can become more aware of alternative cancer treatment methods.
Previously, Mr. Ohri has worked in several areas within the pharmaceutical industry as an executive. He worked for Navin Fluorine International Ltd. as the vice president of business development for CDMO North America from 2011 to 2018 and for NFIL USA Inc., the Group Company of Navin Fluorine International Ltd., as the president beginning in 2018. Since 2023, he has further lent his expertise to Navin Molecular as the head of North American business.
Mr. Ohri maintains professional alignment with the Association of the Physicians Society, DCAT and the American Society of Clinical Oncology, and he is a Charter Member of NJ TIE and the Orphan Drug Congress. Exceptionally proud of his work with The Alka Ohri Foundation, as well as his vision and passion, he is committed to dedicating his time and resources to furthering his philanthropic efforts to positively impact the world.
Contact Mr. Ohri:
